Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1

Inclusion Criteria

• •Hepatitis C virus (HCV) genotype (GT) 1, 2, 3, 4, 5, or 6 infection. Mixed GT and indeterminate GT may be acceptable.
• •Aspartate aminotransferase (AST) to platelet ratio index (APRI) score of less than or equal to 1, at time of screening.
• •Does not have current active hepatitis B virus infection defined as:
• •* positive hepatitis B surface antigen (HBsAg), OR
• •* hepatitis B virus (HBV) deoxyribonucleic acid (DNA) \> lower limit of quantification (LLOQ) in subjects with isolated positive anti-hepatitis B core (HBc) (i.e., negative HBsAg and anti-hepatitis B surface\[HBs\])
• •Platelets ≥ 150,000 cells/mm³
• •Albumin ≥ lower limit of normal (LLN)
• •Positive anti-HCV antibody (Ab) AND plasma HCV ribonucleic acid (RNA) viral load ≥ 1,000 IU/mL at Screening and for at least 6 months before Screening.
• •No past history/evidence of cirrhosis.
• •No history of hepatocellular carcinoma.
• •Hepatitis C virus treatment-naïve (had not received a single dose of any approved or investigational anti-HCV medication).
• •If female, the subject must not be pregnant, breastfeeding, or considering becoming pregnant during the study and for 30 days after the last dose of study drug.